NCT06912087 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06912087
Title	Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	University of Chicago
Indications	hypopharynx cancer laryngeal squamous cell carcinoma oropharynx cancer nasopharynx carcinoma head and neck squamous cell carcinoma oral squamous cell carcinoma nasal cavity carcinoma
Therapies	Cetuximab + Pembrolizumab + XL092
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 1 of 1 entries

Facility	Status	City	State	Zip	Country	Details
University of Chicago Medicine Comprehensive Cancer Center		Chicago	Illinois	60637	United States	Details

Showing 1 to 1 of 1 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06912087Clinical Trial Detail